ScriptLinkRx Resources
Compounding Guides for Providers
Provider guides to compounded medications and regulatory updates for clinics ordering from 503A compounding pharmacies and 503B outsourcing facilities.
Guides for Clinics
Practical guides to choosing and running a compounded-medication program
503A vs 503B Compounding: What Clinics Need to Know Before Ordering
503A pharmacies fill prescriptions for named patients; 503B outsourcing facilities supply office stock. How the two differ and which one a clinic needs.
How to Choose a Compounding Pharmacy Ordering Platform: A 2026 Guide for Clinics
A neutral checklist for clinics comparing compounding pharmacy ordering platforms: licensing, 503A/503B access, pricing, compliance and red flags.
Regulatory Updates
FDA, PCAC and state developments that change how clinics source compounded medications
FDA's Proposal to Exclude Semaglutide, Tirzepatide and Liraglutide From the 503B Bulks List
On April 30, 2026 the FDA proposed removing semaglutide, tirzepatide and liraglutide from the 503B bulks list. What it means for office-use ordering.
FDA's September 2026 Warning Letter to Empower: What It Means for Clinics Ordering Compounded GLP-1s
The FDA's September 18, 2026 warning letter called semaglutide-B12 and tirzepatide-niacinamide compounds essentially copies. What clinics should change.
PCAC's July 2026 Peptide Votes: BPC-157, TB-500 and What Happens Next
The FDA's PCAC voted to recommend BPC-157, TB-500, KPV, MOTS-c, Semax and Epitalon for the 503A bulks list. What the votes mean and what to watch.
GLP-1 & Metabolic
Incretin-based formulations for weight-management and metabolic programs
Compounded Semaglutide with Cyanocobalamin (B12): What Providers Should Know
Compounded semaglutide with B12: regulatory status after the shortage resolution, additive justification, and pharmacy vetting questions for providers.
Compounded Semaglutide with Pyridoxine (B6): A Provider's Guide
What clinics should know about compounded semaglutide with pyridoxine (B6): regulatory status after the 2025 shortage resolution, sourcing, and quality.
Compounded Tirzepatide with Cyanocobalamin (B12): What Providers Should Know
Regulatory status, additive justification, and sourcing questions for compounded tirzepatide with B12 — a provider-focused guide, updated November 2026.
Compounded Tirzepatide with L-Carnitine: A Provider's Overview
A provider guide to compounded tirzepatide with L-carnitine: regulatory status, FDA combination scrutiny, and sourcing questions for clinics.
Compounded Tirzepatide with NAD+ and L-Carnitine: Provider Considerations
A regulatory overview of compounded tirzepatide with NAD+ and L-carnitine for providers: the essentially-a-copy framework and two-additive scrutiny.
Compounded Tirzepatide with Pyridoxine (B6): A Provider's Guide
A provider guide to compounded tirzepatide with pyridoxine (B6): essentially-a-copy limits, the 2026 503B bulks proposal, and pharmacy quality questions.
Retatrutide: Regulatory Status and What Providers Need to Know
Retatrutide is not FDA-approved and cannot legally be compounded as of November 2026. A regulatory fact check for clinics fielding patient questions.
Peptides Under FDA Review
Peptides under active FDA and PCAC review in 2026
BPC-157: Compounding and Regulatory Status for Providers
A regulatory-literate overview of BPC-157's FDA compounding status in 2026, including the April 2026 Category 2 removal and the July 23–24, 2026 PCAC vote.
TB-500 (Thymosin Beta-4 Fragment): Provider Overview and Regulatory Status
TB-500, a thymosin beta-4 fragment: a provider overview of its class, compounding forms, limited human evidence, and 2026 FDA regulatory status.
Longevity & Wellness
Compounds ordered by longevity and wellness practices
Compounded Glutathione: Forms and Provider Considerations
A provider guide to compounded glutathione: forms, sterile-compounding standards, the endotoxin contamination history, and pharmacy sourcing questions.
Compounded NAD+ for Clinics: Forms, Practice Context, and Sourcing
A provider guide to compounded NAD+: what it is, how longevity and wellness clinics use it, its forms, and sterile-compounding questions to ask a pharmacy.
Hormone & Growth
GH-axis and hormone-adjacent formulations
Sexual Wellness
Sexual-health formulations and their regulatory context
Bremelanotide (PT-141): Compounded Forms and Provider Considerations
A regulatory-literate overview of compounded PT-141 (bremelanotide) for clinics: mechanism, forms, essentially-a-copy analysis, and sourcing due diligence.
Compounded Oxytocin: What Providers Should Know
A regulatory guide to compounded oxytocin for clinics: nasal spray and troche forms, off-label context, FDA status, and pharmacy sourcing questions.
Skin & Aesthetics
Topical and aesthetic formulations for dermatology and med spas